A Prospective Observational Study of Factors Affecting the Change in Quality of Life in Patients With Primary Aldosteronism After Treatment
Authors' conclusion
Correction of hypokalemia and control of diastolic blood pressure are essential factors contributing to the improvement in the HRQoL in patients with PA regardless of the standardized treatment received.
Study context
- Population
- Patients with PA, included November 2020 to March 2022
- Participants
- 116 patients
- Exposure
- PA patients after 12 months of standardized treatment vs baseline
- Outcome
- Change in HRQoL (SF-36 dimension and total scores) and factors affecting it
- Follow-up
- 12 months of treatment
Main finding
As reported in the abstract
SF-36 HRQoL · 1-year follow-up
- 6 of 8 SF-36 dimensions and SF-36 total score significantly improved vs baseline
- all P < .05
- Health-related quality of life (HRQoL) improvement correlated with change in blood potassium level (multiple linear regression)
- P = .007
- HRQoL improvement correlated with change in systolic blood pressure (multiple linear regression)
- P = .003
Observational data: associations, not effects.
Further findings
ARR, blood pressure and hypokalemia after treatment vs baseline
- ARR decreased
- Z = −4.967, P < .001
- Systolic blood pressure decreased
- t = 8.985, P < .001
- Diastolic blood pressure decreased
- t = 7.233, P < .001
- Hypokalemia effectively corrected
- χ2 = 69.014, P < .001
Original publication
A Prospective Observational Study of Factors Affecting the Change in Quality of Life in Patients With Primary Aldosteronism After Treatment. Endocr Pract. Published 18 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →